Amgen Articles
US 1st-quarter results continue to flow in
3 May 2000
Stock Commentary Europe
27 April 2000
Amgen wins infringement ruling in EPO case
27 April 2000
Management change at Amgen
6 April 2000
SkyePharma signs drug development deal with Amgen
6 April 2000
Patent hearing over Epogen starts
3 April 2000
Stock Commentary New York
23 March 2000
Stock Commentary New York
2 March 2000
Kirin looking to triple revenues
2 March 2000
Drab week for pharma stocks
1 March 2000
Stock Commentary New York
24 February 2000
Amgen files first regulatory dossiers for NESP and Kineret
27 January 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
Amgen and J&J fight it out over Procrit
20 January 2000
Abbott option for $2 bill stake in SuperGen
7 January 2000
Amgen chairman retires
9 December 1999
Yamanouchi watching Lipitor developments
24 November 1999
New Amgen RA drug candidates, data presented at ACR
18 November 1999
Guilford sees progress across R&D programs
4 November 1999
Epogen gets pediatric indication approval in USA
4 November 1999
Amgen finds key AD protein
28 October 1999
Appointment at Amgen
28 October 1999
FDA backs pediatric indication for Epogen
28 October 1999
Stock Commentary New York
28 October 1999
Amgen profits grow strongly in 3rd qtr
22 October 1999
Amgen opens new EPO facility
11 October 1999
Stock Commentary New York
11 October 1999
Stock Commentary New York
30 September 1999
NESP pivotal data put Amgen in position to add $1 billion-plus to EPO
29 September 1999
Amgen amends patent case against GA-EPO
23 September 1999
Japan's drugmakers will have to "globalize"
10 September 1999
Stock Commentary New York
19 August 1999
Neuroimmunophilin enters clinical trials
5 August 1999
Amgen corrects IL-1ra statement
29 July 1999
Stock Commentary New York
15 July 1999
ClinPhone appointment
24 June 1999
HMR settles Cardizem CD suit with Andrx
16 June 1999
Schering-Plough heads S&P 500 health co list
29 March 1999
US biotech drug sales to grow 13% pa to 2002
29 March 1999
Amgen sets aside $100m for abarelix in 1999
18 March 1999
Stock Commentary New York
18 March 1999
IDEC looking to hit acquisition trail
16 March 1999
Stock Commentary New York
4 March 1999
Future growth of the global pharmaceutical market evaluated by MSDW
23 February 1999
Medicare issues in 106th Congress
26 January 1999
Medicare issues in 106th Congress
22 January 1999
Celera deal with Amgen
18 January 1999
Stock Commentary New York
7 January 1999
J&J loses out to Amgen on exclusive rights to NESP
23 December 1998
Stock Commentary New York
10 December 1998
Amgen Outlines Business Strategy For Sustaining Growth
25 November 1998
Goldman Sachs, MSDW Top II's 1998 Analysts List
10 November 1998
UK Biotech Firms Back In Vogue With Investors?
5 November 1998
Latest Wave Of US 1st Quarter Results
29 October 1998
Stock Commentary New York
29 October 1998
Amgen's Epogen Once-A-Week Safe, But Who Will Sell It?
29 October 1998
Amgen Australia to market The Liposome Company's Abelcet
15 October 1998
The Emerging Role Of Anticytokine Therapy
1 October 1998
Amgen, J&J Spat Over EPO Mimic
1 October 1998
Stock Commentary
24 September 1998
Maxim And BioNative's RCC Collaboration
21 September 1998
Amgen Drops MGDF In All Indications
17 September 1998
Battle On As Biotech Looks For New Ways Of Funding
8 September 1998
Amgen Stops MGDF Platelet Donor Trials
20 August 1998
R-PR's DNA Patent Position Focused, But Vulnerable?
20 August 1998
Amgen's Stemgen Backed For US Approval
6 August 1998
United Therapeutics Appointment
6 August 1998
W-L's Lipitor "Will Be World Top-Seller In 2005"
3 August 1998
Healthy Second-Quarter Growth For US Drug Firms
29 July 1998
Amgen Appointment
23 July 1998
Alizyme "Catapulted Into Clinical Arena"
23 July 1998
US Advisory Panel Meetings
22 July 1998
Amgen Wins EPO Patent Dispute
16 July 1998
Small-Molecule G-CSF Developed
16 July 1998
J&J Takeover Of Amgen, Rumor Or Reality?
30 June 1998
UK Pharma Leaders Outline Strategy
22 June 1998
Euro Researchers Rate Lilly For Clinical Trials
18 June 1998
Stock Commentary New York
4 June 1998
Stock Commentary New York
28 May 1998
DuPont Planning Amgen Takeover?
26 May 1998
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
